Neuropathix (NPTX) 10-K 9 Apr 19 2018 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	Apr. 01, 2019	Dec. 31, 2018	Jun. 30, 2018
Details
Registrant Name		Kannalife Inc
Registrant CIK		0001615999
SEC Form		10-K
Period End date		Dec. 31, 2018
Fiscal Year End		--12-31
Trading Symbol		tygs
Tax Identification Number (TIN)		462645343
Number of common stock shares outstanding	69,854,141
Public Float			$ 0
Filer Category		Non-accelerated Filer
Current with reporting		Yes
Voluntary filer		No
Well-known Seasoned Issuer		No
Shell Company		false
Small Business		true
Emerging Growth Company		true
Ex Transition Period		false
Amendment Flag		false
Document Fiscal Year Focus		2018
Document Fiscal Period Focus		FY
Entity File Number		000-55657
Entity Information, Former Legal or Registered Name		TYG Solutions Corp.
Entity Incorporation, State Country Name		Delaware
Entity Address, Address Line One		3805 Old Easton Road
Entity Address, City or Town		Doylestown
Entity Address, State or Province		PA
Entity Address, Address Description		Address of principal executive offices including Zip Code
City Area Code		858
Local Phone Number		883-2642
Phone Fax Number Description		Registrant’s telephone number, including area code
Entity Listing, Par Value Per Share	$ 0.0001

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2018	Dec. 31, 2017
CURRENT ASSETS:
Cash and cash equivalents	$ 307,131	$ 4,326
Marketable security (available for sale)	2,579,640	0
Other receivables	99,691	400
Due from related party, net	16,334	0
Total Current Assets	3,002,796	4,726
Investment	0	256,359
Property and equipment, net	3,074	0
Security deposits	17,121	15,000
Deferred tax asset	0	772,000
TOTAL ASSETS	3,022,991	1,048,085
CURRENT LIABILITIES:
Accounts payable and accrued expenses	283,996	453,632
Payroll and related liabilities	246,067	239,924
Notes payable	0	367,500
Loan payable - related party	16,173	0
Total Current Liabilities	546,236	1,061,056
LONG TERM LIABILITIES:
Payroll and related liabilities - long term	0	2,812,810
Loan payable - long term	620,000	0
Loan payable - related party - long term	25,822	0
Convertible notes payable - long term	500,000	185,000
Convertible notes payable - related party - long term	0	288,981
Total Long Term Liabilities	1,145,822	3,286,791
TOTAL LIABILITIES	1,692,058	4,347,847
STOCKHOLDERS' EQUITY (DEFICIENCY):
Common Stock, Value, Issued	6,985	5,328
Additional paid-in capital	6,381,755	2,683,776
Accumulated deficit	(5,052,051)	(5,988,866)
Non-controlling interest	(5,756)	0
TOTAL STOCKHOLDERS' EQUITY (DEFICIENCY)	1,330,933	(3,299,762)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY)	3,022,991	1,048,085
Series A Preferred Stock
STOCKHOLDERS' EQUITY (DEFICIENCY):
Preferred Stock, Value, Issued	0	0
Series B Preferred Stock
STOCKHOLDERS' EQUITY (DEFICIENCY):
Preferred Stock, Value, Issued	$ 0	$ 0

Consolidated Balance Sheets - P

Consolidated Balance Sheets - Parenthetical - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	69,854,141	53,281,932
Common Stock, Shares, Outstanding	69,854,141	53,281,932
Series A Preferred Stock
Preferred Stock, Shares Authorized	75	75
Preferred Stock, Shares Issued	75	0
Preferred Stock, Shares Outstanding	75	0
Temporary Equity, Liquidation Preference	$ 75,000	$ 75,000
Series B Preferred Stock
Preferred Stock, Shares Authorized	75	75
Preferred Stock, Shares Issued	75	0
Preferred Stock, Shares Outstanding	75	0
Temporary Equity, Liquidation Preference	$ 75,000	$ 75,000

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
NET REVENUES:
Grant Revenue	$ 173,889	$ 0
TOTAL NET REVENUES	173,889	0
OPERATING EXPENSES:
Research and development	224,933	4,000
General and administrative	1,010,764	1,190,362
TOTAL OPERATING EXPENSES	1,235,697	1,194,362
LOSS FROM OPERATIONS	(1,061,808)	(1,194,362)
OTHER (EXPENSE) INCOME:
Interest income (expense), net	(30,764)	(98,893)
Other (expense) income, net	36,183	0
Loss on conversion of convertible debt	(61,815)	0
Gain on settlement	3,901,974	0
Realized loss on marketable security	(167,034)	0
Unrealized loss on marketable security	(873,693)	0
TOTAL OTHER (EXPENSE) INCOME	2,804,851	(98,893)
NET INCOME (LOSS) BEFORE INCOME TAX	1,743,043	(1,293,255)
Income tax expense (benefit)	811,984	350,000
NET INCOME (LOSS)	931,059	(1,643,255)
Net income (loss) attributable to noncontrolling interests	(5,756)	0
Net income (loss) attributable to Kannalife, Inc.	$ 936,815	$ (1,643,255)
Income (Loss) attributable to Kannalife, Inc. per common share - basic	$ 0.01	$ (0.03)
Income (Loss) attributable to Kannalife, Inc. per common share - diluted	$ 0.01	$ (0.03)
Weighted average common shares outstanding - basic	64,417,684	48,504,268
Weighted average common shares outstanding - diluted	68,849,054	48,504,268

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity (Deficiency) - USD ($)	Series A Preferred Stock	Series B Preferred Stock	Common Stock	Additional Paid-in Capital	Retained Earnings	Noncontrolling Interest	Total
Equity Balance, Starting at Dec. 31, 2016	$ 0	$ 0	$ 5,328	$ 2,679,578	$ (4,345,611)	$ 0	$ (1,660,705)
Shares Outstanding, Starting at Dec. 31, 2016	0	0	53,281,932
Stock Issued During Period, Value, Issued for Services	$ 0	$ 0	$ 0	4,198	0	0	4,198
Stock Issued During Period, Shares, Issued for Services	0	0	0
Net Income (Loss)	$ 0	$ 0	$ 0	0	(1,643,255)	0	(1,643,255)
Shares Outstanding, Ending at Dec. 31, 2017	0	0	53,281,932
Equity Balance, Ending at Dec. 31, 2017	$ 0	$ 0	$ 5,328	2,683,776	(5,988,866)	0	(3,299,762)
Stock Issued During Period, Value, Issued for Services	$ 0	$ 0	$ 0	10,077	0	0	10,077
Stock Issued During Period, Shares, Issued for Services	0	0	0
Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments	$ 0	$ 0	$ 153	653,940	0	0	654,093
Stock Issued During Period, Shares, Conversion of Convertible Securities	0	0	1,537,009
Shares Granted, Value, Share-based Payment Arrangement, after Forfeiture	$ 0	$ 0	$ 551	2,812,260	0	0	2,812,811
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	0	0	5,505,200
Issuance of Series A Preferred stock for cash	$ 0	$ 0	$ 0	75,000	0	0	75,000
Issuance of Series A Preferred stock for cash, shares	75	0	0
Issuance of Series B Preferred stock for cash	$ 0	$ 0	$ 0	75,000	0	0	75,000
Issuance of Series B Preferred stock for cash, shares	0	75	0
Stock Issued During Period, Value, New Issues	$ 0	$ 0	$ 203	202,797	0	0	203,000
Stock Issued During Period, Shares, New Issues	0	0	2,030,000
Effect of reverse recapitalization transaction	$ 0	$ 0	$ 750	(131,095)	0	0	(130,345)
Effect of reverse recapitalization transaction, shares	0	0	7,500,000
Net Income (Loss)	$ 0	$ 0	$ 0	0	936,815	(5,756)	931,059
Shares Outstanding, Ending at Dec. 31, 2018	75	75	69,854,141
Equity Balance, Ending at Dec. 31, 2018	$ 0	$ 0	$ 6,985	$ 6,381,755	$ (5,052,051)	$ (5,756)	$ 1,330,933

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$ 931,059	$ (1,643,255)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Loss on issuance of stock for conversion of notes payable and accrued salaries	61,815	0
Gain on settlement	(3,901,974)	0
Realized loss on marketable security	167,034	0
Unrealized loss on marketable security	873,693	0
Amortization of debt discount	0	14,310
Issuance of options for services	10,077	4,198
Provision for deferred income taxes	772,000	350,000
Changes in operating assets and liabilities:
Security deposits	(2,121)	0
Other receivables	(99,291)	0
Accounts payable and accrued expenses	(29,342)	(81,481)
Payroll and related liabilities	6,143	963,868
NET CASH USED IN OPERATING ACTIVITIES	(1,210,907)	(392,360)
CASH FLOWS FROM INVESTING ACTIVITIES:
Cash received upon reverse acquisition	289,654	0
Proceeds from sale of marketable securities	537,966	0
Purchase of equipment	(3,074)	0
NET CASH PROVIDED BY INVESTING ACTIVITIES	824,546	0
CASH FLOWS FROM FINANCING ACTIVITIES:
Due from related party, net	(16,334)	0
Proceeds from issuance of Series A Preferred stock	75,000	0
Proceeds from issuance of Series B Preferred stock	75,000	0
Proceeds from issuance of common stock	203,000	0
Proceeds from notes payable	352,500	0
Proceeds from notes payable - related party	0	367,500
Proceeds from convertible notes payable - related party	0	20,000
Repayments on convertible notes payable related party	0	(23,828)
NET CASH PROVIDED BY FINANCING ACTIVITIES	689,166	363,672
Net increase (decrease) in cash	302,805	(28,688)
Cash and cash equivalents, beginning of year	4,326	33,014
Cash and cash equivalents, end of year	307,131	4,326
NON-CASH ACTIVITIES:
Issuance of common stock for conversion of notes payable and accrued interest	236,104	0
Issuance of common stock for conversion of notes payable and accrued interest - related party	356,176	0
Issuance of common stock for conversion of accrued salaries	2,812,811	0
Issuance of common stock upon for liabilities assumed in reverse acquisition	$ 130,345	$ 0

Note 1 - Organization and Natur

Note 1 - Organization and Nature of Operations	12 Months Ended
	Dec. 31, 2018
Notes
Note 1 - Organization and Nature of Operations	NOTE 1 – ORGANIZATION AND NATURE OF OPERATIONS Kannalife, Inc. (the “Company”) was incorporated under the laws of the state of Delaware on March 25, 2013 under the name TYG Solutions Corp. The Company consummated a share exchange transaction on July 25, 2018 with Kannalife Sciences, Inc. (“Kannalife”), a privately held Delaware corporation formed in 2010, the accounting acquirer. Upon completion of the share exchange transaction, Kannalife is treated as the surviving entity and accounting acquirer although the Company was the legal acquirer. Accordingly, the Company’s historical financial statements are those of Kannalife the surviving entity and accounting acquirer. All references that refer to (the “Company” or “we” or “us” or “our”) are Kannalife, unless otherwise differentiated. Kannalife is a phytomedical/pharmaceutical company that specializes in the research and development of synthetic molecules and therapeutic products derived from botanical sources, including the cannabis taxa. Share Exchange and Corporate Restructuring On July 25, 2018, the Company entered into a Share Exchange Agreement (the “Share Exchange Agreement”) with Kannalife Sciences, Inc., a Delaware corporation (“Kannalife”) and certain stockholders of Kannalife (the “Kannalife Stockholders”). Pursuant to the terms of the Share Exchange Agreement, the Company acquired approximately 99.7% of the issued and outstanding shares of Kannalife by means of a share exchange with the Kannalife Stockholders in exchange for 60,324,141 newly issued shares of the common stock of the Company (the “Share Exchange”), which increased the Company's issued and outstanding shares of common stock to 69,854,141. As a result of the Share Exchange, Kannalife became a 99.7% owned subsidiary of the Company, which on a going forward basis will result in consolidated financial reporting by the Company to include the results of Kannalife. The initial closing of the Share Exchange occurred concurrently with entry into the Share Exchange Agreement (the “Initial Closing”). After the Initial Closing and for a period of no more than 120 days thereafter, unless extended in the sole discretion of the Company, the Company may issue, on the same terms and conditions as those contained in the Share Exchange Agreement, additional shares of the common stock of the Company to Kannalife Stockholders that did not participate in the Initial Closing, provided that each additional Kannalife Stockholder becomes a party to the transaction documents (the “Additional Closing”). The Share Exchange has been accounted for as a reverse acquisition of the Company by Kannalife but in substance as a capital transaction, rather than a business combination since the Company had nominal operations and assets prior to and as of the closing of the Share Exchange. The former stockholders of Kannalife represent a significant constituency of the Company’s voting power immediately following the Share Exchange and Kannalife’s management has assumed operational, financial and governance control. The transaction is deemed a reverse recapitalization and the accounting is similar to that resulting from a reverse acquisition, except that no goodwill or other intangible assets should be recorded. For accounting purposes, Kannalife is treated as the surviving entity and accounting acquirer although the Company was the legal acquirer. Accordingly, the Company’s historical financial statements are those of Kannalife. All references to common stock, share and per share amounts have been retroactively restated to reflect the reverse recapitalization as if the transaction had taken place as of the beginning of the earliest period presented. Company assets and liabilities pre-acquisition: Cash and cash equivalents 289,654 Note receivable 142,500 Total assets 432,154 Accounts payable and accrued expenses 20,504 Loan payable - related party - long term 41,995 Convertible notes payable - related party 500,000 Total liabilities 562,499 Total liabilities assumed (130,345) The following summarized unaudited consolidated pro forma information shows the results of operations of the Company had the reverse acquisition occurred on January 1, 2018 and 2017, respectively: Pro Forma (Unaudited) Years Ended December 31, 2018 2017 Total revenues $ 173,889 $ 1,154 Net income (loss) $ 819,105 $ (1,665,698) Net income (loss) per common share, basic $ 0.01 $ (0.03) Net income (loss) per common share, diluted $ 0.01 $ (0.03) The summarized consolidated pro forma results are not necessarily indicative of results which would have occurred if the reverse acquisition had been in effect for the periods presented. Further, the summarized unaudited consolidated pro forma results are not intended to be a projection of future results. Name Change On November 9, 2018, the Company filed an amendment to its certificate of incorporation with the Delaware Secretary of State to change its name to Kannalife, Inc. The Company has concurrently submitted a request to FINRA for approval of the name change as well as a ticker symbol change and is awaiting approval. The Company’s name change and ticker change was reviewed and processed by FINRA and went effective January 17, 2019.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Notes
Note 2 - Summary of Significant Accounting Policies	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES The significant accounting policies used in the preparation of the consolidated financial statements are as follows: Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP. Principles of Consolidation The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (“ASC 810”). The consolidated financial statements include the accounts of the Company and its majority owned subsidiary, Kannalife. The non-controlling interest in Kannalife represents the 0.30% equity interest held by the original shareholders of Kannalife before the share exchange. All significant consolidated transactions and balances have been eliminated in consolidation. The operations of Kannalife, Inc. are included in the consolidated financial statement from the date of the Share Exchange. Noncontrolling Interests The Company accounts for its less than 100% interests in Kannalife in accordance with ASC Topic 810, Consolidation, and accordingly the Company presents noncontrolling interests as a component of equity on its consolidated balance sheet and reports the noncontrolling interest’s share of Kannalife’s net loss attributable to noncontrolling interests in the consolidated statement of operations. Significant risks and uncertainties The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital. The Company currently has no commercially approved products and there can be no assurance that the Company’s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property. Use of Estimates The preparation of consolidated financial statements and accompanying notes in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the periods. Actual results could differ from those estimates. Significant matters requiring the use of estimates and assumptions include, but are not necessarily limited to, establishing the fair value of marketable securities and periodically evaluating marketable securities for potential impairment, fair value of the Company’s stock, stock-based compensation, and valuation allowance relating to the Company’s deferred tax assets. Management believes that its estimates and assumptions are reasonable, based on information that is available at the time they are made. Cash and Cash Equivalents Our cash and cash equivalents include short-term, highly liquid investments with original maturities of three months or less when purchased. At times throughout the year, the Company may maintain bank balances that could exceed Federal Deposit Insurance Corporation insured limits. The Company maintains its cash deposit accounts with high credit quality financial institutions, and therefore believes that its loss exposure is minimal. Accounts Receivable Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions and sets up an allowance for doubtful accounts when collection is uncertain. Customers’ accounts are written off when all attempts to collect have been exhausted. Recoveries of accounts receivable previously written off are recorded as income when received. As of December 31, 2018 and 2017, the Company had no allowance for doubtful account. Concentration Risks As of December 31, 2108, the Company’s revenue had a concentration of 100% from one grant. The concentration of the Company’s revenue creates a potential risk to future working capital in the event that the Company is not able to continue receiving the grant revenue. As of December 31, 2108, the Company’s accounts receivable had a concentration of 80% and 20% from two separate parties. The concentration of the Company’s accounts receivable creates a potential risk to future working capital in the event that the Company is not able to collect all, or a majority, of outstanding accounts receivable balances. Revenue Recognition The FASB issued Accounting Standards Update (“ASU”) No. 2014-09, codified as ASC 606: Revenue from Contracts with Customers, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The Company adopted ASC 606 effective January 1, 2018 using modified retrospective basis and the cumulative effect was immaterial to the consolidated financial statements. Revenue consists of research funding from the Company’s National Institute of Health (“NIH”) Grant. Grant revenue is recognized when qualifying costs are incurred and there is reasonable assurance that the conditions of the award have been met for collection. Proceeds received prior to the costs being incurred or the conditions of the award being met are recognized as deferred revenue until the services are performed and the conditions of the award are met. Equity Investments Effective January 1, 2018, with the adoption of ASU 2016-01, our accounting treatment for equity investments differs for those with and without readily determinable fair values. Equity investments with readily determinable fair values are recorded at fair value with changes in fair value recorded in “Unrealized Gain/Loss On Investments.” For equity investments without readily determinable fair values we have elected the “measurement alternative,” and therefore carry these investments at cost, less impairment (if any), plus or minus changes in observable prices. On a quarterly basis, we review our equity investments without readily determinable fair values for impairment. We consider a number of qualitative factors such as whether there is a significant deterioration in earnings performance, credit rating, asset quality, or business prospects of the investee in determining if impairment exists. If the investment is considered impaired, an impairment loss equal to the amount by which the carrying value exceeds its fair value is recorded through a charge to earnings. The impairment loss may be reversed in a subsequent period if there are observable transactions for the identical or similar investment of the same issuer at a higher amount than the carrying amount that was established when the impairment was recognized. Impairment as well as upward or downward adjustments resulting from observable price changes in orderly transactions for identical or similar investments are included in “Income - other.” Realized gains or losses resulting from the sale of equity investments are calculated using the specific identification method and are included in “Realized loss on marketable security". Income Taxes The Company accounts for income taxes under FASB ASC Topic 740, Income Taxes Preferred Stock The Company applies the guidance enumerated in FASB ASC Topic 480, Distinguishing Liabilities from Equity Convertible Instruments The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC Topic 815, Derivatives and Hedging Activities Applicable U.S. GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The Company accounts for convertible instruments (when the Company has determined that the embedded conversion options should not be bifurcated from their host instruments) as follows. The Company records, when necessary, deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares. Stock Based Compensation The Company accounts for share-based compensation in accordance with the fair value recognition provision of FASB ASC 718, Compensation – Stock Compensation The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of FASB ASC 505, Equity–based Payments to Non-Employees . Net Income (Loss) per Share Basic net loss per share is calculated by dividing the net loss for the period by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing income for the period by the weighted-average number of common shares outstanding during the period, increased by potentially dilutive common shares ("dilutive securities") that were outstanding during the period. Dilutive securities include stock options and warrants granted, convertible debt, and convertible preferred stock. In accordance with ASC 260, “Earnings Per Share”, the following table reconciles basic shares outstanding to fully diluted shares outstanding for the year ended December 31, 2018: December 31, 2018 Weighted average number of common shares outstanding - Basic 64,417,684 Series A preferred stock 37,603 Series B preferred stock 37,603 Convertible notes payable 4,356,164 Weighted average number of common and equivalent shares outstanding-Diluted 68,849,054 Common stock equivalents are included in the diluted income per share calculation only when option exercise prices are lower than the average market price of the common shares for the period presented. One hundred thousand (100,000) options were not included in the calculation of net loss per common share for the year ended December 31, 2018 because their effect would be anti-dilutive. The potentially dilutive securities were not included in the calculation of net loss per common share for the year ended December 31, 2017 because their effect would be anti-dilutive. Research and Development In accordance with FASB ASC 730, Research and Development Recently Issued Authoritative Guidance In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“Topic 606”), which is a new comprehensive revenue recognition model that will supersede all existing revenue recognition guidance under U.S. GAAP. The standard requires a company to recognize revenue when it transfers goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This standard is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, with early adoption permitted for interim and annual periods beginning after December 15, 2016. Entities will have the option of using either a full retrospective approach or a modified approach to adopt the guidance in the ASU. We adopted this ASU in the first quarter of 2018 with no material impact to our consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), requiring lessees to recognize for all leases (with the exception of short-term leases) at the commencement date: (1) a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis, and (2) a right-of-use (“ROU”) asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. The update is effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. The Company currently anticipates that upon adoption of the new standard, ROU assets and lease liabilities will be recognized in amounts that will be immaterial to the consolidated balance sheets.

Note 3 - Going Concern and Mana

Note 3 - Going Concern and Management's Liquidity Plans	12 Months Ended
	Dec. 31, 2018
Notes
Note 3 - Going Concern and Management's Liquidity Plans	NOTE 3 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS The Company’s consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in our accompanying consolidated financial statements, the Company has had a net loss from operations of $1,061,808 and $1,194,362 for the years ended December 31, 2018 and 2017, respectively. The net cash used in operations were $1,210,907 and $392,360 for the years ended December 31, 2018 and 2017, respectively. Additionally, the Company had an accumulated deficit of $5,052,051 at December 31, 2018 and has not yet established an adequate ongoing source of revenues sufficient to cover its operating costs and to allow it to continue as a going concern. As of December 31, 2018, we had $307,131 in cash and cash equivalents. Additionally, we had $2,579,640 in marketable securities (available for sale). Management plans to raise additional capital through the sale of our marketable securities. We expect that between our existing cash, cash equivalents and marketable securities we will be able to sufficiently fund our operations and capital requirements for the next 18 months. The Company’s history of recurring losses, and uncertainties as to whether its operations will become profitable and generate operating cash flows raise substantial doubt about its ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2018
Notes
Note 4 - Fair Value Measurements	NOTE 4 – FAIR VALUE MEASUREMENTS The Company follows FASB ASC 820, Fair Value Measurements and Disclosures Level 1 Quoted market prices available in active markets for identical assets or liabilities as of the reporting date. Level 2 Pricing inputs other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reporting date. Level 3 Pricing inputs that are generally unobservable inputs and not corroborated by market data. Financial assets are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies or similar techniques and at least one significant model assumption or input is unobservable. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument. The carrying amounts reported in the Company’s consolidated financial statements for cash, accounts payable and accrued expenses approximate their fair value because of the immediate or short-term nature of these financial instruments. Transactions involving related parties cannot be presumed to be carried out on an arm's-length basis, as the requisite conditions of competitive, free-market dealings may not exist. Representations about transactions with related parties, if made, shall not imply that the related party transactions were consummated on terms equivalent to those that prevail in arm's-length transactions unless such representations can be substantiated. On March 7, 2014, Kannalife Sciences, Inc. (“Kannalife”) entered into an agreement with General Hemp LLC (“General Hemp”) through its wholly owned subsidiary Kannaway LLC (“Kannaway”) for certain rights and agreements to where each company would exchange 4.99% of each Company’s equity, by way of a stock swap. As such, Kannalife would receive a 4.99% equity stake in Kannaway and Kannaway would receive 6,408,980 shares of restricted common stock of Kannalife. On or about April 2014, Kannalife delivered 6,408,980 of the aforementioned Kannalife restricted common stock to General Hemp on behalf of Kannaway and such shares were made to Kannaway as the beneficiary. The Company recorded the fair market value of the common stock at $256,359 or $0.04. The Company valued the shares based upon other transactions of the Company's common stock around the same time frame. The Company accounted for the transaction as a cost investment. On or about December 2015, Medical Marijuana, Inc. (“MJNA”) purchased Kannaway from General Hemp for which due to a dispute between the Company and General Hemp, the Company wasn't provided any of the consideration. On June 1, 2018, the Company received 41,583,333 shares of MJNA common stock pursuant to a settlement agreement effective July 15, 2017. MJNA is a significant shareholder of the Company and their Chief Executive Officer is also on the Company's Board of Directors. The following table presents assets that are measured and recognized at fair value as of December 31, 2018, on a recurring basis: December 31, 2018 Level 1 Level 2 Level 3 Total Carrying Value Marketable securities – Medical Marijuana, Inc. $ 2,579,640 - - $ 2,579,640

Note 5 - Accrued Payroll and Pa

Note 5 - Accrued Payroll and Payroll Taxes	12 Months Ended
	Dec. 31, 2018
Notes
Note 5 - Accrued Payroll and Payroll Taxes	NOTE 5 – ACCRUED PAYROLL AND PAYROLL TAXES Accrued payroll and payroll taxes at December 31, 2018 and 2017 consisted of the following: 2018 2017 Payroll $ - $ 2,812,810 Payroll taxes 246,067 239,924 Totals $ 246,067 $ 3,052,734 As of December 31, 2018 and 2017, the Company has accrued payroll taxes in connection salaries paid and accrued to four officers of the Company. In July of 2018, the Company entered into a new employment agreement with our CEO. The initial term of the agreement is for two years and automatically renews for successive one year terms. In July of 2018, the Company entered into new employment agreements with three officers. The initial term of these agreements are for one year and automatically renew for successive six month terms. See Note 13 for discussion of accrued payroll converted into common stock.

Note 6 - Notes Payable

Note 6 - Notes Payable	12 Months Ended
	Dec. 31, 2018
Notes
Note 6 - Notes Payable	NOTE 6 – NOTES PAYABLE During the year ended December 31, 2017, the Company borrowed $367,500 and issued a promissory note with a maturity date of October 18, 2017. This note was later amended to extend the maturity to April 18, 2019. During the year ended December 31, 2018, the Company borrowed an additional $352,500 and issued a promissory note with a maturity date of April 18, 2019. These loans incurred 3% interest per annum. On June 29, 2018, these notes were amended to extend the maturity date to July 1, 2020 and the interest rate was changed to 8% per annum. All accrued interest prior the amendment date was forgiven. Accrued interest related to these notes is $24,460 and $3,565 as of December 31, 2018 and 2017, respectively. Upon the consolidation of the Company and Kannalife, $100,000 of the above-mentioned borrowings was eliminated due to it being an intercompany transaction. The total, above mentioned, notes payable due is $620,000 as of December 31, 2018. Total interest expense on notes payable, amounted to $24,460 and $3,565 for the years ended December 31, 2018 and 2017, respectively. As of December 31, 2017, this note holder was considered a related party. As of December 31, 2018, due to the proceeds from marketable securities this note holder has no significant influence on the Company and is no longer deemed a related party.

Note 7 - Notes Payable - Relate

Note 7 - Notes Payable - Related Party	12 Months Ended
	Dec. 31, 2018
Notes
Note 7 - Notes Payable - Related Party	NOTE 7 – NOTES PAYABLE – RELATED PARTY Prior to the share exchange agreement, the Company borrowed $25,822 and issued a promissory note with a maturity date of March 31, 2020. The loans represent working capital advances from shareholders, are unsecured, interest bearing 0.5%, and grant a security interest in the Company’s assets as collateral. Accrued interest related to this note is $226 as of December 31, 2018. As of December 31, 2018, due to related parties amounted to $16,173. The amounts due related parties represent working capital advances and fees for work performed by officers and shareholders, are unsecured, non-interest bearing and are due upon demand. Total interest expense on notes payable, amounted to $54 and $0 for the years ended December 31, 2018 and 2017, respectively.

Note 8 - Convertible Notes Paya

Note 8 - Convertible Notes Payable	12 Months Ended
	Dec. 31, 2018
Notes
Note 8 - Convertible Notes Payable	NOTE 8 – CONVERTIBLE NOTES PAYABLE On May 15, 2015, the Company borrowed $35,000 and issued a convertible promissory note with a maturity date of April 30, 2016. The loan incurs 10% interest per annum. This note is convertible to the Company’s common stock at a price of $1.00 per share. In addition, the Company issued 17,500 warrants to purchase common stock with an exercise price of $1.50 per share and a term of two years. These warrants were valued at $7,525 on a relative fair value basis and were recorded as a debt discount to be amortized over the term. Accrued interest related to this note is $0 and $9,196 as of December 31, 2018 and 2017, respectively. On August 13, 2015, the Company borrowed $50,000 and issued a convertible promissory note with a maturity date of August 12, 2016. The loan incurs 10% interest per annum and increasing to 17% per annum in the event of a default. This note is convertible to the Company’s common stock at a price of $1.00 per share. In addition, the Company issued 25,000 warrants to purchase common stock with an exercise price of $1.50 per share and a term of two years. These warrants were valued at $10,751 on a relative fair value basis and were recorded as a debt discount to be amortized over the term. Accrued interest related to this note is $0 and $16,659 as of December 31, 2018 and 2017, respectively. On November 25, 2015, the Company borrowed $100,000 and issued a convertible promissory note with a maturity date of November 24, 2016. The loan incurs 10% interest per annum and increasing to 14% per annum in the event of a default. This note is convertible to the Company’s common stock at a price of $1.00 per share. In addition, the Company issued 50,000 warrants to purchase common stock with an exercise price of $1.50 per share and a term of two years. These warrants were valued at $21,500 on a relative fair value basis and were recorded as a debt discount to be amortized over the term. Accrued interest related to this note is $0 and $25,249 as of December 31, 2018 and 2017, respectively. Prior to the Share Exchange, the Company issued a convertible note to an investor, face value $500,000, in exchange for $500,000 in cash. The note is unsecured, bears interest at the rate of 3% per annum and matures on February 16, 2030. The note is convertible into common stock of the Company at $0.10 per share at any time at the option of the holder, subject to a 4.9% blocking provision which prohibits the holder from converting into common stock of the Company if such conversion results in the holder owning greater than 4.9% of the outstanding common stock of the Company after giving effect to the conversion. Accrued interest related to this note is $13,083 as of December 31, 2018. Total interest expense on convertible notes payable, inclusive of amortization of debt discount of $0 and $14,310, amounted to $6,250 and $65,687 for the years ended December 31, 2018 and 2017, respectively. On January 3, 2018, prior to the Share Exchange, the Company issued 563,063 shares of common stock (on a post-Share Exchange basis) for the conversion of $236,104 convertible notes payable and related accrued interest. The Company recorded a loss of $3,515 on conversion based upon the difference between the fair market value of the Company's common stock and the liabilities relieved. The Company determined that the transaction should be recorded at fair value due to the difference between the conversion price and the price per the agreements.

Note 9 - Convertible Notes Paya

Note 9 - Convertible Notes Payable - Related Party	12 Months Ended
	Dec. 31, 2018
Notes
Note 9 - Convertible Notes Payable - Related Party	NOTE 9 – CONVERTIBLE NOTES PAYABLE - RELATED PARTY On December 27, 2014, the Company borrowed $150,000 from a stockholder and issued a convertible promissory note with a maturity date of December 31, 2015. The loan incurs 10% interest per annum and increasing to 17% per annum in the event of a default. This note is convertible to the Company’s common stock at a price of $1.00 per share. Accrued interest related to this note is $0 and $67,195 as of December 31, 2018 and 2017, respectively. During the year ended December 31, 2015, the Company borrowed $120,000 from the Chief Executive Officer and issued convertible promissory notes that are due on demand. The loans incur 10% interest per annum. These notes are convertible to the Company’s common stock at a price of $1.00 per share. On November 20, 2015, the Company borrowed $5,000 from the Chief Executive Officer and issued a convertible promissory note that is due on demand. The loan incurs 10% interest per annum. This note is convertible to the Company’s common stock at a price of $0.40 per share. During the year ended December 31, 2016, the Company borrowed $15,000 from the Chief Executive Officer and issued convertible promissory notes that are due on demand. The loans incur 10% interest per annum. These notes are convertible to the Company’s common stock at a price of $0.40 per share. During the year ended December 31, 2016, the Company borrowed $10,000 from the Chief Executive Officer and issued convertible promissory notes with a maturity date of December 31, 2016. The loans incur 10% interest per annum and increasing to 17% per annum in the event of a default. These notes are convertible to the Company’s common stock at a price of $0.40 per share. During the year ended December 31, 2017, the Company borrowed $20,000 from the Chief Executive Officer and issued convertible promissory notes with a maturity date of December 31, 2017. The loans incur 10% interest per annum and increasing to 17% per annum in the event of a default. These notes are convertible to the Company’s common stock at a price of $0.40 per share. During the year ended December 31, 2017, the Company repaid $23,828 of principal and $16,522 of accrued interest towards the outstanding notes payable. As of December 31, 2017, $138,981 in principal and $0 of accrued interest was due. On January 3, 2018, prior to the Share Exchange, the Company converted these notes into 973,946 shares of common stock (on a post-Share Exchange basis) valued at $414,476. The difference of the $58,300 balance of the notes and the fair value of the shares issued was recorded as a loss on conversion of debt. The Company determined that the transaction should be recorded at fair value due to the difference between the conversion price and the price per the agreements. Total interest expense on these convertible notes payable amounted to $0 and $16,552 for the years ended December 31, 2018 and 2017, respectively.

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Notes
Note 10 - Commitments and Contingencies	NOTE 10 – COMMITMENTS AND CONTINGENCIES Legal Proceedings From time to time the Company may get involved in legal proceedings arising in the ordinary course of business. Other than as set forth in “Legal Proceedings” in Part II below, the Company believes there is no litigation pending that could have, individually or in the aggregate, a material adverse effect on its results of operations or financial condition. Occupancy Leases On April 1, 2014, the Company entered into a one year lease arrangement for office space, with the option to renew the lease annually. The lease has been renewed through April 2020. The On September 15, 2015, the Company entered into a one year lease arrangement for office space. The Company has amended this lease to extend the term through September 30, 2018. The On February 1, 2018, the Company entered into a month to month lease arrangement for laboratory space. The On July 1, 2018, the Company entered into a one year lease arrangement for office space, with the option to renew the lease annually. On September 1, 2018, the Company subleased this office space to a third party. The Subleasee will pay 100% of rent for months September through November 2018 and will pay 50% of rent until expiration of lease on June 30, 2019. The Royalty Agreements On June 12, 2012, the Company entered into a Patent License Agreement with agencies of the United States Public Health Services within the Department of Health and Human Services (“PHS”). Under the License Agreement, PHS granted the Company an exclusive right to use and develop certain patents relating to Cannabinoids as Antioxidants and Neuroprotectants. In exchange for the License, the Company has agreed to the following payments: · · · · · · · · On December 31, 2014, the Company executed five exclusive pharmaceutical license agreements with the Company’s CEO, the Company’s CMO, three advisory board members of the Company, and an unrelated third party. These agreements provide the Company the worldwide exclusive rights to certain drug technologies and methods (and systems) for collection, processing and use of data for the dispensing of phyto-medical and botanically derived materials for consumption. The license agreements grant to the Company from the inventors the rights to develop, market, make, use, and sell certain drug formulations, which are applied to humans through the use of certain drug technology. In return for these exclusive rights from the inventors, the Company has agreed to compensate the inventors under the agreements with royalties ranging from 1.5% to 2.5% on all net sales by the Company of licensed products covered by a valid claim of a patent or patent application of the inventor patent rights. Additionally, the Company retains the rights to sublicense the drug formulations, and upon such sublicense shall pay the inventors from 1.5% up to 5% of all royalties and sublicense fees paid to the Company on account of sublicenses under the inventor patent rights and inventor technology rights, less all appropriate expenses associated with such sublicenses incurred by the Company. However, if the inventor supplies licensed products to sublicensees of the Company pursuant to such sublicenses, the inventor shall supply such licensed products at its cost. Prior to the Share Exchange these royalty agreements were terminated.

Note 11 - Related Party Transac

Note 11 - Related Party Transactions	12 Months Ended
	Dec. 31, 2018
Notes
Note 11 - Related Party Transactions	NOTE 11 – RELATED PARTY TRANSACTIONS The Company’s Chief Executive Officer shares the use of the leased office space for personal living quarters. The CEO reimburses the Company for 50% of the monthly rent, or $2,700 per month. From time to time the Company sends money to Golden Gate Capital (“GGCP”), a company owned by our CEO, for the advances of certain expenses and to be deposited into the bank account of Kannalife. Due to the timing of the funds transferred and expenses incurred, at times, there remains a balance due from GGCP. As of December 31, 2018, $16,334 is due from GGCP. Subsequent to the period end, GGCP has transferred all the remaining funds to Kannalife. As of the filing of these consolidated financial statements, there is no outstanding balance due from GGCP. See Notes 7, 9 and 13 for additional related party transactions.

Note 12 - Marketable Security

Note 12 - Marketable Security	12 Months Ended
	Dec. 31, 2018
Notes
Note 12 - Marketable Security	NOTE 12 – MARKETABLE SECURITY On June 1, 2018, the Company received 41,583,333 shares of Medical Marijuana, Inc. (“MJNA”) common stock pursuant to a settlement agreement. In 2014, the Company entered into a revenue sharing agreement with Kannaway LLC, whereas, among the considerations and obligations the parties agreed to a share exchange, whereby the Company issued 6,408,980 shares of its common stock in exchange of 4.99% ownership of Kannaway. A significant shareholder of the Company owned the remaining ownership of Kannaway LLC. Subsequently, Kannaway was sold, by its parent company, to MJNA for 833,333,333 shares of MJNA common stock. The settlement agreement called for the release of all obligations in exchange for the issuance of 41,583,333 shares of common stock in MJNA to the Company. The investment in MJNA has been recorded as an investment in non-consolidated entities and is revalued every quarter with fluctuations in fair value recorded to earnings. The fair value of the investment is based on the closing price of the shares reported on the principal stock exchange on which they are traded. At December 31, 2018, the Company held 34,533,333 shares of MJNA which traded at a closing price of $0.0747, or value of $2,579,640. For the year ended December 31, 2018, the Company recorded a realized gain of $3,901,974 upon the settlement and receipt of these shares and an unrealized loss of $873,693 related to the investment in MJNA. The gain was netted against the Company's cost basis investment of $256,759 in Kannaway LLC. See note 2 for additional information.

Note 13 - Stockholders' Equity

Note 13 - Stockholders' Equity (Deficiency)	12 Months Ended
	Dec. 31, 2018
Notes
Note 13 - Stockholders' Equity (Deficiency)	NOTE 13 – STOCKHOLDERS’ EQUITY (DEFICIENCY) Series A Preferred Stock – Kannalife Pre-Share Exchange As of December 31, 2017, the Company had a total of 20,000,000 shares of Series A Preferred Stock, $0.001 par value authorized for issuance. Each share of Series A Preferred Stock is convertible into one share of common stock without any additional consideration by the holder, at any time after the date of issuance. The holders of shares of Series A Preferred Stock are entitled to receive dividends, if and when declared by the Board of Directors, at the rate of 8% per annum of the original price of Series A Preferred Stock. In the event of the liquidation the holders of the Series A Preferred Stock are entitled to receive an amount equal to the original Series A price for each share of Series A then held by such holder. Each holder of shares of Series A Preferred Stock is entitled to the number of votes equal to the number of shares of common stock into which such holder’s shares of Series A could be converted on the record date for the vote or written consent of the stockholders. The Series A Preferred Stock is nonredeemable. As of December 31, 2017, there were 4,893,510 shares of Series A Preferred Stock issued and outstanding. In July 2018, prior to the Share Exchange, the Company converted 4,893,510 shares of preferred stock into 4,893,510 shares of common stock (on a post-Share Exchange basis). The presentation on the consolidated balance sheet shows as if these shares were converted as of December 31, 2017. Series A Preferred Stock Effective May 3, 2018, the Company’s Board of Directors authorized and designated 75 shares of the Company’s Preferred Stock as Series A Preferred Stock. Each share of the Series A Preferred Stock is entitled to a liquidation preference of $1,000 per share and is convertible into 1,000 shares of the Company’s common stock. The holders of a majority of the Series A Preferred Stock are entitled to elect up to four (4) directors to the Company’s board of directors and any annual or special meeting and have preferential rights in regard to the election of Series A directors. In all other voting matters, the holders of Series A Preferred Stock are entitled to cast 1,000 votes per share. In July 2018, the Company issued 75 shares of Series A Preferred Stock, to Naturewell, Inc., an entity controlled by the former CEO of TYG Solutions Corp. in exchange for $75,000. Series B Preferred Stock Effective May 3, 2018, the Company’s Board of Directors authorized and designated 75 shares of the Company’s Preferred Stock as Series B Preferred Stock. Each share of the Series B Preferred Stock is entitled to a liquidation preference of $1,000 per share and is convertible into 1,000 shares of the Company’s common stock. The holders of a majority of the Series B Preferred Stock are entitled to elect up to three (3) directors to the Company’s board of directors and any annual or special meeting and have preferential rights in regard to the election of Series B directors. In all other voting matters, the holders of Series B Preferred Stock are entitled to cast 1,000 votes per share. In July 2018, the Company issued 75 shares of Series B Preferred Stock to our CEO in exchange for $75,000. Common Stock The Company is authorized to issue 200,000,000 shares of $0.0001 par value common stock. All common stock shares have equal voting rights, are non-assessable and have one vote per share. Voting rights are not cumulative and, therefore, the holders of more than 50% of the common stock could, if they choose to do so, elect all of the directors of the Company, subject to the rights of the preferred stockholders. On January 3, 2018, prior to the Share Exchange, the Company issued 5,505,200 shares of common stock (on a post-Share Exchange basis) to four officers, valued at $2,342,813, for the conversion of accrued salaries. The difference of $469,997 between the balance of accrued salaries and the fair value of the shares issued was recorded as a capital contribution recorded within additional paid-in capital. The transaction was viewed as being on behalf of the Company in connection with the pending share exchange transaction. In July 2018, the Company issued 2,030,000 shares of common stock, to an entity commonly controlled by the $500,000 convertible note holder, in exchange for $203,000. As of December 31, 2018 and 2017, there were 69,854,141 and 53,281,932 shares of common stock issued and outstanding, respectively. See Note 8 and 9 for discussion of the conversion of notes payable and accrued interest into common stock. The Company determined fair value of its shares of common and preferred stock based on the price at which the Company was selling its shares of common and preferred stock to third party investors. Stock Options On September 1, 2017, the Company entered into an agreement for consulting services. As compensation the Company granted options to purchase 100,000 shares of common stock at a price of $2.00 per share and are exercisable for five years. The stock option vests in equal monthly installments of 24 months. These options were valued at $20,154 using a Black-Scholes Options Pricing Model. For the years ended December 31, 2018 and 2017, the Company recorded $10,077 and $4,198, respectively, as stock based compensation which is included in the general and administrative expenses in the consolidated statement of operations. The remaining compensation expense outstanding for future periods is $5,878. The fair value of the options is estimated using a Black-Scholes Options Pricing Model with the following assumptions: Market value of common stock on issuance date $ 0.40 Exercise price $ 2.00 Expected volatility 100% Expected term (in years) 5 Risk-free interest rate 1.73% Expected dividend yields - Warrants The following is a summary of outstanding and exercisable warrants: Number of Shares Weighted Average Exercise Price Year of Expiration Balance at December 31, 2016 92,500 1.5 2017 Issued - - - Expired (92,500) 1.5 2017 Balance at December 31, 2017 - - - Issued - - - Expired - - - Balance at December 31, 2018 - - - The Company did not issue any warrants for the years ended December 31, 2018 and 2017.

Note 14 - Income Taxes

Note 14 - Income Taxes	12 Months Ended
	Dec. 31, 2018
Notes
Note 14 - Income Taxes	NOTE 14 – INCOME TAXES We file income tax returns in the United States federal jurisdiction and in various state and local jurisdictions. In the normal course of business, we are subject to examination by taxing authorities. The tax years ending 2015 through 2018 remain subject to examination for federal tax purposes and remain subject to examination in significant state tax jurisdictions. On December 22, 2017, the United States enacted significant changes to the U.S. tax law following the passage and signing of H.R.1, "An Act to Provide for Reconciliation Pursuant to Titles II and V of the Concurrent Resolution on the Budget for Fiscal Year 2018" (the "Tax Act") (previously known as "The Tax Cuts and Jobs Act"). The Tax Act significantly revised the U.S. corporate income tax regime by, among other things, lowering the corporate tax rate from 35% to 21%. The Tax Act reduced the U.S. corporate income tax rate reduction to 21% becomes effective January 1, 2018. The Company re-measured its deferred tax assets and liabilities as of December 31, 2017, applying the reduced corporate income tax rate and recorded a provisional decrease to the deferred tax assets of $787,700, with a corresponding adjustment to the valuation allowance. As of December 31, 2018 and 2017, the Company had federal and state net operating loss carry forwards of $862,000 and $3,425,000, respectively, that may be offset against future taxable income which will begin to expire in 2032 through 2038. The reconciliation of income tax expense computed at the U.S. federal statutory rate to the income tax provision for the years ended December 31, 2018 and 2017 is as follows: For the Years ended December 31, US 2018 2017 Income (loss) before income taxes $ 1,743,043 $ (1,293,255) Income tax expense (benefit) at statutory rates 366,039 (439,700) State income taxes, net of federal benefit 48,035 (60,500) Permanent Differences 10,724 3,300 Change in Federal Rates - 788,100 Change in Valuation Allowance 387,517 58,800 Other (331) - Income tax expense (benefit) $ 811,984 $ 350,000 The change in the Company's net increase in the valuation allowance was caused by the change in estimation of NOL utilization. Deferred income taxes reflect the net tax effects of: (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes; and (b) operating loss and tax credit carry-forwards. We record net deferred tax assets to the extent we believe these assets will more likely than not be realized. In making such determination, we consider all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax planning strategies and recent financial operations. Significant components of deferred tax assets as December 31, 2018 and 2017 were as follows: For the Years ended December 31, 2018 2017 Deferred Tax Assets: Federal net operating loss carryforwards $ 181,023 $ 719,400 Capital Losses over Capital Gains (17,290) (16,700) Non-cash interest 29,132 53,200 Non-cash accrued compensation 825,713 788,200 Mark to Market Adjustment - Investments held for sale 240,965 State taxes 92,298 192,100 Net deferred tax assets before valuation allowance 1,351,841 1,736,200 Valuation Allowance (1,351,841) (964,200) Net Deferred Tax Assets $ - $ 772,000 Reconciliation of the statutory federal income tax to the Company's effective tax: For the Years ended December 31, 2018 2017 % % Statutory federal tax rate 21 34 State taxes, net of federal benefit 2.76 4.68 Change in Federal Rates 0 -60.94 Valuation allowance 22.23 -4.55 Other, net 0.6 -0.26 Provision for income taxes 46.59 -27.06 Utilization of the net operating losses (NOL) carryforwards may be subject to a substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code (IRC) of 1986, as amended (the Code), as well as similar state provisions. These ownership changes may limit the amount of NOL carryforwards that can be utilized annually to offset future taxable income. In general, an “ownership change” as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders. At the time of closing the books, the Company had not yet completed a study to determine the extent of the limitation.

Note 15 - Subsequent Events

Note 15 - Subsequent Events	12 Months Ended
	Dec. 31, 2018
Notes
Note 15 - Subsequent Events	NOTE 15 – SUBSEQUENT EVENTS The Company has evaluated subsequent events through the date these consolidated financial statements were issued.

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies: Basis of Presentation (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Basis of Presentation	Basis of Presentation The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States, or GAAP.

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies: Principles of Consolidation (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Principles of Consolidation	Principles of Consolidation The Company evaluates the need to consolidate affiliates based on standards set forth in ASC 810 Consolidation (“ASC 810”). The consolidated financial statements include the accounts of the Company and its majority owned subsidiary, Kannalife. The non-controlling interest in Kannalife represents the 0.30% equity interest held by the original shareholders of Kannalife before the share exchange. All significant consolidated transactions and balances have been eliminated in consolidation. The operations of Kannalife, Inc. are included in the consolidated financial statement from the date of the Share Exchange.

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies: Noncontrolling Interests (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Noncontrolling Interests	Noncontrolling Interests The Company accounts for its less than 100% interests in Kannalife in accordance with ASC Topic 810, Consolidation, and accordingly the Company presents noncontrolling interests as a component of equity on its consolidated balance sheet and reports the noncontrolling interest’s share of Kannalife’s net loss attributable to noncontrolling interests in the consolidated statement of operations.

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies: Significant risks and uncertainties (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Significant risks and uncertainties	Significant risks and uncertainties The Company’s operations are subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to: the results of clinical testing and trial activities of the Company’s products, the Company’s ability to obtain regulatory approval to market its products, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, Company products, the Company’s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its products, and the Company’s ability to raise capital. The Company currently has no commercially approved products and there can be no assurance that the Company’s research and development will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting intellectual property.

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies: Use of Estimates (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Use of Estimates	Use of Estimates The preparation of consolidated financial statements and accompanying notes in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the dates of the consolidated financial statements, and the reported amounts of revenues and expenses during the periods. Actual results could differ from those estimates. Significant matters requiring the use of estimates and assumptions include, but are not necessarily limited to, establishing the fair value of marketable securities and periodically evaluating marketable securities for potential impairment, fair value of the Company’s stock, stock-based compensation, and valuation allowance relating to the Company’s deferred tax assets. Management believes that its estimates and assumptions are reasonable, based on information that is available at the time they are made.

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies: Cash and Cash Equivalents (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Cash and Cash Equivalents	Cash and Cash Equivalents Our cash and cash equivalents include short-term, highly liquid investments with original maturities of three months or less when purchased. At times throughout the year, the Company may maintain bank balances that could exceed Federal Deposit Insurance Corporation insured limits. The Company maintains its cash deposit accounts with high credit quality financial institutions, and therefore believes that its loss exposure is minimal.

Note 2 - Summary of Significa_8

Note 2 - Summary of Significant Accounting Policies: Accounts Receivable (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Accounts Receivable	Accounts Receivable Accounts receivable are carried at original invoice amount less an estimate made for doubtful accounts based on a review of all outstanding amounts. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer’s financial condition, credit history and current economic conditions and sets up an allowance for doubtful accounts when collection is uncertain. Customers’ accounts are written off when all attempts to collect have been exhausted. Recoveries of accounts receivable previously written off are recorded as income when received. As of December 31, 2018 and 2017, the Company had no allowance for doubtful account.

Note 2 - Summary of Significa_9

Note 2 - Summary of Significant Accounting Policies: Concentration Risks (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Concentration Risks	Concentration Risks As of December 31, 2108, the Company’s revenue had a concentration of 100% from one grant. The concentration of the Company’s revenue creates a potential risk to future working capital in the event that the Company is not able to continue receiving the grant revenue. As of December 31, 2108, the Company’s accounts receivable had a concentration of 80% and 20% from two separate parties. The concentration of the Company’s accounts receivable creates a potential risk to future working capital in the event that the Company is not able to collect all, or a majority, of outstanding accounts receivable balances.

Note 2 - Summary of Signific_10

Note 2 - Summary of Significant Accounting Policies: Revenue Recognition (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Revenue Recognition	Revenue Recognition The FASB issued Accounting Standards Update (“ASU”) No. 2014-09, codified as ASC 606: Revenue from Contracts with Customers, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. The Company adopted ASC 606 effective January 1, 2018 using modified retrospective basis and the cumulative effect was immaterial to the consolidated financial statements. Revenue consists of research funding from the Company’s National Institute of Health (“NIH”) Grant. Grant revenue is recognized when qualifying costs are incurred and there is reasonable assurance that the conditions of the award have been met for collection. Proceeds received prior to the costs being incurred or the conditions of the award being met are recognized as deferred revenue until the services are performed and the conditions of the award are met.

Note 2 - Summary of Signific_11

Note 2 - Summary of Significant Accounting Policies: Equity Investments (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Equity Investments	Equity Investments Effective January 1, 2018, with the adoption of ASU 2016-01, our accounting treatment for equity investments differs for those with and without readily determinable fair values. Equity investments with readily determinable fair values are recorded at fair value with changes in fair value recorded in “Unrealized Gain/Loss On Investments.” For equity investments without readily determinable fair values we have elected the “measurement alternative,” and therefore carry these investments at cost, less impairment (if any), plus or minus changes in observable prices. On a quarterly basis, we review our equity investments without readily determinable fair values for impairment. We consider a number of qualitative factors such as whether there is a significant deterioration in earnings performance, credit rating, asset quality, or business prospects of the investee in determining if impairment exists. If the investment is considered impaired, an impairment loss equal to the amount by which the carrying value exceeds its fair value is recorded through a charge to earnings. The impairment loss may be reversed in a subsequent period if there are observable transactions for the identical or similar investment of the same issuer at a higher amount than the carrying amount that was established when the impairment was recognized. Impairment as well as upward or downward adjustments resulting from observable price changes in orderly transactions for identical or similar investments are included in “Income - other.” Realized gains or losses resulting from the sale of equity investments are calculated using the specific identification method and are included in “Realized loss on marketable security".

Note 2 - Summary of Signific_12

Note 2 - Summary of Significant Accounting Policies: Income Taxes (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Income Taxes	Income Taxes The Company accounts for income taxes under FASB ASC Topic 740, Income Taxes

Note 2 - Summary of Signific_13

Note 2 - Summary of Significant Accounting Policies: Preferred Stock (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Preferred Stock	Preferred Stock The Company applies the guidance enumerated in FASB ASC Topic 480, Distinguishing Liabilities from Equity

Note 2 - Summary of Signific_14

Note 2 - Summary of Significant Accounting Policies: Convertible Instruments (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Convertible Instruments	Convertible Instruments The Company evaluates and accounts for conversion options embedded in convertible instruments in accordance with ASC Topic 815, Derivatives and Hedging Activities Applicable U.S. GAAP requires companies to bifurcate conversion options from their host instruments and account for them as free standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. The Company accounts for convertible instruments (when the Company has determined that the embedded conversion options should not be bifurcated from their host instruments) as follows. The Company records, when necessary, deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares.

Note 2 - Summary of Signific_15

Note 2 - Summary of Significant Accounting Policies: Stock Based Compensation (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Stock Based Compensation	Stock Based Compensation The Company accounts for share-based compensation in accordance with the fair value recognition provision of FASB ASC 718, Compensation – Stock Compensation The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of FASB ASC 505, Equity–based Payments to Non-Employees .

Note 2 - Summary of Signific_16

Note 2 - Summary of Significant Accounting Policies: Net Income (Loss) per Share (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Net Income (Loss) per Share	Net Income (Loss) per Share Basic net loss per share is calculated by dividing the net loss for the period by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing income for the period by the weighted-average number of common shares outstanding during the period, increased by potentially dilutive common shares ("dilutive securities") that were outstanding during the period. Dilutive securities include stock options and warrants granted, convertible debt, and convertible preferred stock. In accordance with ASC 260, “Earnings Per Share”, the following table reconciles basic shares outstanding to fully diluted shares outstanding for the year ended December 31, 2018: December 31, 2018 Weighted average number of common shares outstanding - Basic 64,417,684 Series A preferred stock 37,603 Series B preferred stock 37,603 Convertible notes payable 4,356,164 Weighted average number of common and equivalent shares outstanding-Diluted 68,849,054 Common stock equivalents are included in the diluted income per share calculation only when option exercise prices are lower than the average market price of the common shares for the period presented. One hundred thousand (100,000) options were not included in the calculation of net loss per common share for the year ended December 31, 2018 because their effect would be anti-dilutive. The potentially dilutive securities were not included in the calculation of net loss per common share for the year ended December 31, 2017 because their effect would be anti-dilutive.

Note 2 - Summary of Signific_17

Note 2 - Summary of Significant Accounting Policies: Research and Development (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Research and Development	Research and Development In accordance with FASB ASC 730, Research and Development

Note 2 - Summary of Signific_18

Note 2 - Summary of Significant Accounting Policies: Recently Issued Authoritative Guidance (Policies)	12 Months Ended
	Dec. 31, 2018
Policies
Recently Issued Authoritative Guidance	Recently Issued Authoritative Guidance In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (“Topic 606”), which is a new comprehensive revenue recognition model that will supersede all existing revenue recognition guidance under U.S. GAAP. The standard requires a company to recognize revenue when it transfers goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This standard is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, with early adoption permitted for interim and annual periods beginning after December 15, 2016. Entities will have the option of using either a full retrospective approach or a modified approach to adopt the guidance in the ASU. We adopted this ASU in the first quarter of 2018 with no material impact to our consolidated financial statements. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), requiring lessees to recognize for all leases (with the exception of short-term leases) at the commencement date: (1) a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis, and (2) a right-of-use (“ROU”) asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. The update is effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. The Company currently anticipates that upon adoption of the new standard, ROU assets and lease liabilities will be recognized in amounts that will be immaterial to the consolidated balance sheets.

Note 1 - Organization and Nat_2

Note 1 - Organization and Nature of Operations: Schedule of pre-acquisition assets and liabilities (Tables)	12 Months Ended
	Dec. 31, 2018
Tables/Schedules
Schedule of pre-acquisition assets and liabilities	Cash and cash equivalents 289,654 Note receivable 142,500 Total assets 432,154 Accounts payable and accrued expenses 20,504 Loan payable - related party - long term 41,995 Convertible notes payable - related party 500,000 Total liabilities 562,499 Total liabilities assumed (130,345)

Note 1 - Organization and Nat_3

Note 1 - Organization and Nature of Operations: Schedule of Consolidated Pro-forma Information showing results of operations (Tables)	12 Months Ended
	Dec. 31, 2018
Tables/Schedules
Schedule of Consolidated Pro-forma Information showing results of operations	Pro Forma (Unaudited) Years Ended December 31, 2018 2017 Total revenues $ 173,889 $ 1,154 Net income (loss) $ 819,105 $ (1,665,698) Net income (loss) per common share, basic $ 0.01 $ (0.03) Net income (loss) per common share, diluted $ 0.01 $ (0.03)

Note 2 - Summary of Signific_19

Note 2 - Summary of Significant Accounting Policies: Net Income (Loss) per Share: Schedule of Reconciliation, basic shares outstanding to fully diluted shares outstanding (Tables)	12 Months Ended
	Dec. 31, 2018
Tables/Schedules
Schedule of Reconciliation, basic shares outstanding to fully diluted shares outstanding	December 31, 2018 Weighted average number of common shares outstanding - Basic 64,417,684 Series A preferred stock 37,603 Series B preferred stock 37,603 Convertible notes payable 4,356,164 Weighted average number of common and equivalent shares outstanding-Diluted 68,849,054

Note 4 - Fair Value Measureme_2

Note 4 - Fair Value Measurements: Schedule of assets that are measured and recognized at fair value (Tables)	12 Months Ended
	Dec. 31, 2018
Tables/Schedules
Schedule of assets that are measured and recognized at fair value	December 31, 2018 Level 1 Level 2 Level 3 Total Carrying Value Marketable securities – Medical Marijuana, Inc. $ 2,579,640 - - $ 2,579,640

Note 5 - Accrued Payroll and _2

Note 5 - Accrued Payroll and Payroll Taxes: Schedule of Accrued payroll and payroll taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Tables/Schedules
Schedule of Accrued payroll and payroll taxes	2018 2017 Payroll $ - $ 2,812,810 Payroll taxes 246,067 239,924 Totals $ 246,067 $ 3,052,734

Note 13 - Stockholders' Equit_2

Note 13 - Stockholders' Equity (Deficiency): Schedule of fair value of the options (Tables)	12 Months Ended
	Dec. 31, 2018
Tables/Schedules
Schedule of fair value of the options	The fair value of the options is estimated using a Black-Scholes Options Pricing Model with the following assumptions: Market value of common stock on issuance date $ 0.40 Exercise price $ 2.00 Expected volatility 100% Expected term (in years) 5 Risk-free interest rate 1.73% Expected dividend yields -

Note 13 - Stockholders' Equit_3

Note 13 - Stockholders' Equity (Deficiency): Schedule of outstanding and exercisable warrants (Tables)	12 Months Ended
	Dec. 31, 2018
Tables/Schedules
Schedule of outstanding and exercisable warrants	Number of Shares Weighted Average Exercise Price Year of Expiration Balance at December 31, 2016 92,500 1.5 2017 Issued - - - Expired (92,500) 1.5 2017 Balance at December 31, 2017 - - - Issued - - - Expired - - - Balance at December 31, 2018 - - -

Note 14 - Income Taxes_ Schedul

Note 14 - Income Taxes: Schedule of Components of Income Tax Expense (Benefit) (Tables)	12 Months Ended
	Dec. 31, 2018
Tables/Schedules
Schedule of Components of Income Tax Expense (Benefit)	For the Years ended December 31, US 2018 2017 Income (loss) before income taxes $ 1,743,043 $ (1,293,255) Income tax expense (benefit) at statutory rates 366,039 (439,700) State income taxes, net of federal benefit 48,035 (60,500) Permanent Differences 10,724 3,300 Change in Federal Rates - 788,100 Change in Valuation Allowance 387,517 58,800 Other (331) - Income tax expense (benefit) $ 811,984 $ 350,000

Note 14 - Income Taxes_ Sched_2

Note 14 - Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Tables)	12 Months Ended
	Dec. 31, 2018
Tables/Schedules
Schedule of Deferred Tax Assets and Liabilities	For the Years ended December 31, 2018 2017 Deferred Tax Assets: Federal net operating loss carryforwards $ 181,023 $ 719,400 Capital Losses over Capital Gains (17,290) (16,700) Non-cash interest 29,132 53,200 Non-cash accrued compensation 825,713 788,200 Mark to Market Adjustment - Investments held for sale 240,965 State taxes 92,298 192,100 Net deferred tax assets before valuation allowance 1,351,841 1,736,200 Valuation Allowance (1,351,841) (964,200) Net Deferred Tax Assets $ - $ 772,000

Note 14 - Income Taxes_ Sched_3

Note 14 - Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Tables)	12 Months Ended
	Dec. 31, 2018
Tables/Schedules
Schedule of Effective Income Tax Rate Reconciliation	For the Years ended December 31, 2018 2017 % % Statutory federal tax rate 21 34 State taxes, net of federal benefit 2.76 4.68 Change in Federal Rates 0 -60.94 Valuation allowance 22.23 -4.55 Other, net 0.6 -0.26 Provision for income taxes 46.59 -27.06

Note 1 - Organization and Nat_4

Note 1 - Organization and Nature of Operations (Details)	12 Months Ended
	Dec. 31, 2018
Details
Entity Incorporation, State Country Name	Delaware
Entity Incorporation, Date of Incorporation	Mar. 25, 2013
Entity Information, Former Legal or Registered Name	TYG Solutions Corp.

Note 1 - Organization and Nat_5

Note 1 - Organization and Nature of Operations: Schedule of pre-acquisition assets and liabilities (Details)	Dec. 31, 2018USD ($)
Details
Pre-acquisition Assets, Cash and cash equivalents	$ 289,654
Pre-acquisition Assets, Note receivable	142,500
Pre-acquisition Assets, Total assets	432,154
Pre-acquisition Liabilities, Accounts payable and accrued expenses	20,504
Pre-acquisition Liabilities, Loan payable - related party - long term	41,995
Pre-acquisition Liabilities, Convertible notes payable - related party	500,000
Pre-acquisition Liabilities, Total liabilities	562,499
Pre-acquisition Liabilities, Total liabilities assumed	$ (130,345)

Note 1 - Organization and Nat_6

Note 1 - Organization and Nature of Operations: Schedule of Consolidated Pro-forma Information showing results of operations (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Details
Pro-forma Information, Total revenues	$ 173,889	$ 1,154
Pro-forma Information, Net income (loss)	$ 819,105	$ (1,665,698)
Pro-forma Information, Net income (loss) per common share, basic	$ 0.01	$ (0.03)
Pro-forma Information, Net income (loss) per common share, diluted	$ 0.01	$ (0.03)

Note 2 - Summary of Signific_20

Note 2 - Summary of Significant Accounting Policies: Net Income (Loss) per Share: Schedule of Reconciliation, basic shares outstanding to fully diluted shares outstanding (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Details
Weighted average common shares outstanding - basic	64,417,684	64,417,684	48,504,268
Series A preferred stock	$ 37,603	$ 37,603
Series B preferred stock	37,603	37,603
Convertible notes payable	$ 4,356,164	$ 4,356,164
Weighted average common shares outstanding - diluted	68,849,054	68,849,054	48,504,268

Note 2 - Summary of Signific_21

Note 2 - Summary of Significant Accounting Policies: Research and Development (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Details
Research and development	$ 224,933	$ 4,000

Note 3 - Going Concern and Ma_2

Note 3 - Going Concern and Management's Liquidity Plans (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Details
LOSS FROM OPERATIONS	$ (1,061,808)	$ (1,194,362)
NET CASH USED IN OPERATING ACTIVITIES	(1,210,907)	(392,360)
Accumulated deficit	$ (5,052,051)	$ (5,988,866)

Note 4 - Fair Value Measureme_3

Note 4 - Fair Value Measurements: Schedule of assets that are measured and recognized at fair value (Details)	Dec. 31, 2018USD ($)
Fair Value, Inputs, Level 1
Marketable securities - Medical Marijuana, Inc	$ 2,579,640
Fair Value, Inputs, Level 2
Marketable securities - Medical Marijuana, Inc	0
Fair Value, Inputs, Level 3
Marketable securities - Medical Marijuana, Inc	0
Marketable securities - Medical Marijuana, Inc	$ 2,579,640

Note 5 - Accrued Payroll and _3

Note 5 - Accrued Payroll and Payroll Taxes: Schedule of Accrued payroll and payroll taxes (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Details
Payroll	$ 0	$ 2,812,810
Payroll taxes	246,067	239,924
Totals	$ 246,067	$ 3,052,734

Note 6 - Notes Payable (Details

Note 6 - Notes Payable (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Notes Payable
Interest Expense	$ 24,460	$ 3,565

Note 7 - Notes Payable - Rela_2

Note 7 - Notes Payable - Related Party (Details) - Notes Payable - Related Party - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Loan payable - related party	$ 16,173
Interest Expense	$ 54	$ 0

Note 8 - Convertible Notes Pa_2

Note 8 - Convertible Notes Payable (Details) - Convertible Notes Payable - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Debt Instrument, Unamortized Discount	$ 0	$ 14,310
Interest Expense	$ 6,250	$ 65,687

Note 9 - Convertible Notes Pa_2

Note 9 - Convertible Notes Payable - Related Party (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Convertible Notes Payable - Related Party
Debt Instrument, Unamortized Discount	$ 0	$ 16,552

Note 13 - Stockholders' Equit_4

Note 13 - Stockholders' Equity (Deficiency) (Details) - $ / shares	Dec. 31, 2018	Dec. 31, 2017
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares, Issued	69,854,141	53,281,932
Common Stock, Shares, Outstanding	69,854,141	53,281,932
Series A Preferred Stock
Preferred Stock, Shares Authorized	75	75
Series B Preferred Stock
Preferred Stock, Shares Authorized	75	75

Note 13 - Stockholders' Equit_5

Note 13 - Stockholders' Equity (Deficiency): Schedule of fair value of the options (Details)	12 Months Ended
	Dec. 31, 2018$ / shares
Details
Fair Value Measurements, Valuation Techniques	Black-Scholes Options Pricing Model
Market value of common stock on issuance date	$ 0.40
Exercise price	$ 2
Expected volatility	1
Expected term (in years)	5 years
Risk-free interest rate	0.0173
Expected dividend yields	0

Note 13 - Stockholders' Equit_6

Note 13 - Stockholders' Equity (Deficiency): Schedule of outstanding and exercisable warrants (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Details
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance	92,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance	$ 1.5
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	0	0
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period	0	(92,500)
Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price	$ 0	$ 1.5
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance	0	92,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance	$ 0	$ 1.5

Note 14 - Income Taxes_ Sched_4

Note 14 - Income Taxes: Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Details
Income (loss) before income taxes	$ 1,743,043	$ (1,293,255)
Income tax expense (benefit) at statutory rates	366,039	(439,700)
State income taxes, net of federal benefit	48,035	(60,500)
Permanent Differences	10,724	3,300
Change in Federal Rates	0	788,100
Change in Valuation Allowance	387,517	58,800
Other	(331)	0
Income tax expense (benefit)	$ 811,984	$ 350,000

Note 14 - Income Taxes_ Sched_5

Note 14 - Income Taxes: Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017
Deferred Tax Assets:
Federal net operating loss carryforwards	$ 181,023	$ 719,400
Capital Losses over Capital Gains	(17,290)	(16,700)
Non-cash interest	29,132	53,200
Non-cash accrued compensation	825,713	788,200
Mark to Market Adjustment - Investments held for sale	240,965
State taxes	92,298	192,100
Net deferred tax assets before valuation allowance	1,351,841	1,736,200
Valuation Allowance	(1,351,841)	(964,200)
Net Deferred Tax Assets	$ 0	$ 772,000

Note 14 - Income Taxes_ Sched_6

Note 14 - Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Details
Statutory federal tax rate	21.00%	34.00%
State taxes, net of federal benefit	2.76%	4.68%
Change in Federal Rates	0.00%	(60.94%)
Valuation allowance	22.23%	(4.55%)
Other, net	0.60%	(0.26%)
Provision for income taxes	46.59%	(27.06%)